Suppliers / ACME Formulation

ACME Formulation

India 343 employees 3 duplicate records merged Updated 9 July 2026

ACME Formulation is a finished-dose manufacturer based in India. It appears in 36 regulatory filings across 10 regulators, without an active US DMF or CEP on file. Its filings concentrate with EFDA (ET), NAFDAC (NG) and EDE (AE). Its GMP standing is certified by EMA, NAFDAC (NG) and MCAZ (ZW). Customs aggregates show $10.4M of exports covering 374 molecules to 45 destinations in 2025.

0
active US DMFs
0
valid CEPs
5
registered plants 1 with an FDA FEI number
36
filings across 10 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Registered plants

Site FDA FEI
CHANGODAR, United Arab Emirates Not on file
Solan, India 3016859498
Nalagarh, India Not on file
Atizapán de Zaragoza, Mexico Not on file
Himachl Pradesh India, Nigeria Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
EFDA (ET) 8 None
NAFDAC (NG) 6 1
EDE (AE) 6 None
TMDA (TZ) 3 None
CDSCO (India) 3 None
ARCSA (EC) 3 None
EMA None 3
MCAZ (ZW) None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $2.3M 20
2025 Not reported $10.4M 45
2024 Not reported $12.3M 38
2023 Not reported $11.3M 41

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. ACME Formulation comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts